Targeting cancer cell survival mechanisms in pancreatic cancer treatment
Official title: Targeting cell regulatory states to complement MEK/autophagy inhibition in pancreatic cancer
Funded at Columbia University Health Sciences · NIH-11001532 · Data updated 2026-11-12
This study is looking at new ways to treat pancreatic cancer by blocking certain pathways that help the cancer survive, with the hope of finding better treatments that can help patients feel better and live longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | December 19, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $524,080 |
| NIH project number | 5R01CA266558-03 |
| Project ID | NIH-11001532 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those who have not responded to existing therapies.
✕Less likely to help
Patients with other types of cancer or those whose pancreatic cancer is not characterized by KRAS mutations may not benefit from this research.
What this research studies
This research investigates new treatment strategies for pancreatic ductal adenocarcinoma (PDAC), a type of cancer known for its resistance to standard therapies. The approach focuses on inhibiting two key pathways, MEK and autophagy, which cancer cells use to survive. By understanding how these pathways interact and contribute to treatment resistance, the research aims to develop more effective therapies that could improve patient outcomes. The study will involve analyzing patient tumor samples and using advanced models to explore the cellular responses to these treatments.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer, potentially improving survival rates.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting MEK and autophagy pathways in cancer treatment, indicating potential for success in this area.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Olive, Kenneth P. — Columbia University Health Sciences
- Study coordinator: Olive, Kenneth P.
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.